MacroGenics IncNASDAQ:MGNX
- LAST PRICE3.0009
- TODAY'S CHANGE (%)-0.0391 (-1.2862%)
- Bid / Lots3.0000/ 12
- Ask / Lots3.0100/ 8
- Open / Previous Close3.0900 / 3.0400
- Day Range
- 52 Week Range
- Volume238,564
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGNX |
|---|---|---|
| 09:32 ET | 1815 | 3.09 |
| 09:34 ET | 500 | 3.05 |
| 09:36 ET | 1100 | 3.08 |
| 09:38 ET | 100 | 3.05 |
| 09:39 ET | 900 | 3.062 |
| 09:41 ET | 1469 | 3.07 |
| 09:43 ET | 1291 | 3.07 |
| 09:45 ET | 1585 | 3.07 |
| 09:48 ET | 3593 | 3.055 |
| 09:50 ET | 10740 | 3.03 |
| 09:52 ET | 4417 | 2.99 |
| 09:54 ET | 10627 | 2.985 |
| 09:56 ET | 820 | 2.985 |
| 09:57 ET | 2300 | 2.9891 |
| 09:59 ET | 338 | 2.985 |
| 10:01 ET | 6211 | 3.005 |
| 10:03 ET | 5964 | 3.015 |
| 10:06 ET | 500 | 3.01 |
| 10:08 ET | 16328 | 3.0285 |
| 10:10 ET | 2008 | 3.01 |
| 10:12 ET | 1350 | 2.991 |
| 10:14 ET | 2600 | 3.015 |
| 10:15 ET | 600 | 3.015 |
| 10:19 ET | 900 | 3.025 |
| 10:21 ET | 950 | 3.015 |
| 10:24 ET | 1200 | 3.01 |
| 10:26 ET | 6956 | 3.015 |
| 10:28 ET | 2390 | 3.015 |
| 10:30 ET | 1400 | 3 |
| 10:32 ET | 900 | 3.01 |
| 10:33 ET | 3200 | 3.02 |
| 10:35 ET | 1399 | 3.03 |
| 10:39 ET | 300 | 3.035 |
| 10:42 ET | 1086 | 3.02 |
| 10:44 ET | 100 | 3.015 |
| 10:46 ET | 100 | 3.01 |
| 10:50 ET | 300 | 3.015 |
| 10:51 ET | 200 | 3.01 |
| 10:53 ET | 1000 | 3.005 |
| 10:55 ET | 700 | 3 |
| 10:57 ET | 1255 | 2.985 |
| 11:00 ET | 100 | 2.985 |
| 11:02 ET | 200 | 2.985 |
| 11:04 ET | 576 | 2.98 |
| 11:06 ET | 1219 | 2.98 |
| 11:08 ET | 100 | 2.985 |
| 11:09 ET | 1961 | 2.995 |
| 11:11 ET | 865 | 2.9989 |
| 11:13 ET | 2184 | 3.005 |
| 11:15 ET | 100 | 3.005 |
| 11:22 ET | 834 | 3.005 |
| 11:24 ET | 2060 | 3.02 |
| 11:27 ET | 700 | 3.02 |
| 11:29 ET | 660 | 3.015 |
| 11:33 ET | 600 | 3.035 |
| 11:36 ET | 1400 | 3.025 |
| 11:38 ET | 200 | 3.025 |
| 11:40 ET | 200 | 3.025 |
| 11:45 ET | 104 | 3.025 |
| 11:47 ET | 226 | 3.025 |
| 11:49 ET | 2600 | 3.033 |
| 11:51 ET | 1404 | 3.035 |
| 11:54 ET | 200 | 3.035 |
| 11:56 ET | 3322 | 3.045 |
| 11:58 ET | 215 | 3.045 |
| 12:00 ET | 100 | 3.045 |
| 12:02 ET | 200 | 3.045 |
| 12:03 ET | 1835 | 3.04 |
| 12:05 ET | 3400 | 3.04 |
| 12:07 ET | 2312 | 3.03 |
| 12:09 ET | 204 | 3.04 |
| 12:12 ET | 450 | 3.03 |
| 12:14 ET | 1324 | 3.025 |
| 12:16 ET | 430 | 3.02 |
| 12:18 ET | 200 | 3.025 |
| 12:20 ET | 928 | 3.015 |
| 12:23 ET | 552 | 3.015 |
| 12:27 ET | 200 | 3.015 |
| 12:30 ET | 400 | 3.015 |
| 12:32 ET | 1170 | 3.015 |
| 12:34 ET | 200 | 3.015 |
| 12:36 ET | 300 | 3.015 |
| 12:38 ET | 300 | 3.015 |
| 12:39 ET | 694 | 3.015 |
| 12:41 ET | 861 | 3.015 |
| 12:43 ET | 500 | 3.0155 |
| 12:48 ET | 1348 | 3.025 |
| 12:50 ET | 229 | 3.025 |
| 12:52 ET | 778 | 3.025 |
| 12:54 ET | 526 | 3.025 |
| 12:56 ET | 1010 | 3.015 |
| 12:57 ET | 200 | 3.015 |
| 12:59 ET | 857 | 3.005 |
| 01:01 ET | 500 | 3.0062 |
| 01:03 ET | 126 | 3.005 |
| 01:06 ET | 2400 | 3.0011 |
| 01:08 ET | 3897 | 2.995 |
| 01:10 ET | 233 | 2.995 |
| 01:12 ET | 100 | 2.995 |
| 01:14 ET | 1795 | 2.99 |
| 01:15 ET | 1221 | 2.985 |
| 01:17 ET | 3200 | 3 |
| 01:21 ET | 5613 | 2.99 |
| 01:24 ET | 5300 | 2.995 |
| 01:26 ET | 1800 | 2.995 |
| 01:28 ET | 829 | 2.995 |
| 01:30 ET | 100 | 2.995 |
| 01:32 ET | 345 | 2.9999 |
| 01:33 ET | 100 | 3 |
| 01:37 ET | 729 | 2.995 |
| 01:39 ET | 3400 | 2.995 |
| 01:44 ET | 500 | 2.995 |
| 01:46 ET | 4341 | 2.995 |
| 01:50 ET | 12985 | 3.005 |
| 01:51 ET | 611 | 3.005 |
| 01:53 ET | 405 | 3.005 |
| 01:55 ET | 2576 | 3.005 |
| 01:57 ET | 300 | 3.01 |
| 02:02 ET | 100 | 3.005 |
| 02:06 ET | 1000 | 3.0009 |
Yesterday
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against MacroGenics, Inc. - MGNX, from 10:00AM ET on Wednesday Sep 25, 2024 by Dow Jones
10:00AM ET on Wednesday Sep 25, 2024 by Dow Jones
Sep 24, 2024
Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MGNX, from 7:04PM ET on Tuesday Sep 24, 2024 by Dow Jones
7:04PM ET on Tuesday Sep 24, 2024 by Dow JonesMGNX DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action - MGNX, from 6:49PM ET on Tuesday Sep 24, 2024 by Dow Jones
6:49PM ET on Tuesday Sep 24, 2024 by Dow JonesLevi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX, from 2:16PM ET on Tuesday Sep 24, 2024 by Dow Jones
2:16PM ET on Tuesday Sep 24, 2024 by Dow JonesFINAL MGNX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds MacroGenics, Inc. Investors to Join the Class Action Lawsuit!, from 2:01PM ET on Tuesday Sep 24, 2024 by Dow Jones
2:01PM ET on Tuesday Sep 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MacroGenics Inc | 190.7M | -1.4x | --- |
Innate Pharma SA | 178.3M | -4.6x | --- |
Adaptimmune Therapeutics PLC | 235.1M | -2.7x | --- |
Codexis Inc | 206.4M | -2.7x | --- |
Repare Therapeutics Inc | 143.5M | -2.1x | --- |
AVITA Medical Inc | 270.6M | -5.4x | --- |
Company Information
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Contact Information
- Headquarters
- 9704 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 301-251-5172
- Fax
- 301-251-5321
Executives
- Independent Chairman of the Board
- William Heiden
- President, Chief Executive Officer, Director
- Scott Koenig
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- James Karrels
- Chief Operating Officer
- Eric Risser
- Senior Vice President - Research, Chief Scientific Officer
- Ezio Bonvini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $190.7M |
|---|---|
Revenue (TTM) | $41.0M |
Shares Outstanding | 62.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.08 |
EPS | $-2.19 |
Book Value | $2.46 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -357.86% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
